TY - JOUR
T1 - CHA2DS2-VASc Score in Predicting Visual Acuity Outcomes Following Retinal Vein Occlusion
AU - Nemet, Achia
AU - Tuuminen, Raimo
AU - Yona, Tzadok
AU - Plopsky, Gilad
AU - Katz, Michal
AU - Glinkin, Natali
AU - Lelchuk, Olga
AU - Pikkel, Joseph
N1 - Publisher Copyright:
Copyright © 2024 Achia Nemet et al.
PY - 2024
Y1 - 2024
N2 - Purpose: To find whether the CHA2DS2-VASc score, a system for stratifying stroke risk among patients with atrial fibrillation, correlates with visual acuity prognosis following retinal vein occlusion (RVO). Participants and Methods: This retrospective study included 83 eyes of 83 patients with a diagnosis of branch or central RVO between June 2017 and August 2022 with at least 12 months of follow-up in Assuta Ashdod Medical Center, Ashdod, Israel. The patients were divided into three groups, with CHA2DS2-VASc scores of 0–2 (N = 31), 3–5 (N = 45), or 6–9 (N = 7). The change in best-corrected visual acuity (BCVA) between the groups was examined about 1 year after the presentation of RVO. Results: The patient mean age was 67.9 ± 13.8 years; 38.6% were women. The mean visual acuity was 0.83 ± 0.67 LogMAR units at the first admission and 0.78 ± 0.80 LogMAR units at the last visit. Patients with a CHA2DS2-VASc score from 6 to 9 had a significantly poorer BCVA prognosis at 1-year (+0.60 ± 0.94 [−0.27, 1.47] LogMAR units) compared to groups with a CHA2DS2-VASc score from 3 to 5 (−0.01 ± 0.65 [−0.20, 0.19] LogMAR units) and a CHA2DS2-VASc score from 0 to 2 (−0.12 ± 0.59 [−0.33, 0.10] LogMAR units) (p = 0.038). Conclusions: Following RVO, patients with a CHA2DS2-VASc score of 6 or higher had a worse prognosis in their visual acuity than patients with a lower score.
AB - Purpose: To find whether the CHA2DS2-VASc score, a system for stratifying stroke risk among patients with atrial fibrillation, correlates with visual acuity prognosis following retinal vein occlusion (RVO). Participants and Methods: This retrospective study included 83 eyes of 83 patients with a diagnosis of branch or central RVO between June 2017 and August 2022 with at least 12 months of follow-up in Assuta Ashdod Medical Center, Ashdod, Israel. The patients were divided into three groups, with CHA2DS2-VASc scores of 0–2 (N = 31), 3–5 (N = 45), or 6–9 (N = 7). The change in best-corrected visual acuity (BCVA) between the groups was examined about 1 year after the presentation of RVO. Results: The patient mean age was 67.9 ± 13.8 years; 38.6% were women. The mean visual acuity was 0.83 ± 0.67 LogMAR units at the first admission and 0.78 ± 0.80 LogMAR units at the last visit. Patients with a CHA2DS2-VASc score from 6 to 9 had a significantly poorer BCVA prognosis at 1-year (+0.60 ± 0.94 [−0.27, 1.47] LogMAR units) compared to groups with a CHA2DS2-VASc score from 3 to 5 (−0.01 ± 0.65 [−0.20, 0.19] LogMAR units) and a CHA2DS2-VASc score from 0 to 2 (−0.12 ± 0.59 [−0.33, 0.10] LogMAR units) (p = 0.038). Conclusions: Following RVO, patients with a CHA2DS2-VASc score of 6 or higher had a worse prognosis in their visual acuity than patients with a lower score.
KW - CHADS-VASc score
KW - retinal vein occlusion
KW - visual acuity
UR - http://www.scopus.com/inward/record.url?scp=105004579401&partnerID=8YFLogxK
U2 - 10.1155/2024/3054783
DO - 10.1155/2024/3054783
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 39473606
AN - SCOPUS:105004579401
SN - 2090-004X
VL - 2024
JO - Journal of Ophthalmology
JF - Journal of Ophthalmology
IS - 1
M1 - 3054783
ER -